HUP0200552A2 - Use of apoptosis inducing agents in the treatment of (auto)immune diseases - Google Patents

Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Info

Publication number
HUP0200552A2
HUP0200552A2 HU0200552A HUP0200552A HUP0200552A2 HU P0200552 A2 HUP0200552 A2 HU P0200552A2 HU 0200552 A HU0200552 A HU 0200552A HU P0200552 A HUP0200552 A HU P0200552A HU P0200552 A2 HUP0200552 A2 HU P0200552A2
Authority
HU
Hungary
Prior art keywords
auto
treatment
immune diseases
inducing agents
apoptosis inducing
Prior art date
Application number
HU0200552A
Other languages
English (en)
Inventor
Mathieu Hubertus Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of HUP0200552A2 publication Critical patent/HUP0200552A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HU0200552A 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases HUP0200552A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11

Publications (1)

Publication Number Publication Date
HUP0200552A2 true HUP0200552A2 (en) 2002-06-29

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200552A HUP0200552A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Country Status (18)

Country Link
US (1) US20050271624A1 (hu)
EP (1) EP1143994B1 (hu)
JP (1) JP2003500336A (hu)
AT (1) ATE244014T1 (hu)
AU (1) AU3083500A (hu)
CA (1) CA2359392A1 (hu)
DE (1) DE60003632T2 (hu)
DK (1) DK1143994T3 (hu)
EA (1) EA200100770A1 (hu)
ES (1) ES2202039T3 (hu)
HU (1) HUP0200552A2 (hu)
IL (2) IL144228A0 (hu)
MX (1) MXPA01006998A (hu)
NO (1) NO20013397L (hu)
PT (1) PT1143994E (hu)
TR (1) TR200102713T2 (hu)
WO (1) WO2000041497A2 (hu)
ZA (1) ZA200105632B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079222A2 (en) * 2001-03-30 2002-10-10 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
US6924266B2 (en) * 2001-05-25 2005-08-02 Nymox Corporation NTP-peptides and method for removal of tumors
PL207588B1 (pl) * 2001-07-19 2011-01-31 Nymox Corp Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
JP2001516210A (ja) * 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody

Also Published As

Publication number Publication date
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
DE60003632D1 (de) 2003-08-07
EA200100770A1 (ru) 2002-02-28
PT1143994E (pt) 2003-11-28
NO20013397L (no) 2001-09-11
ZA200105632B (en) 2002-10-09
TR200102713T2 (tr) 2002-05-21
ATE244014T1 (de) 2003-07-15
IL144228A0 (en) 2002-05-23
EP1143994B1 (en) 2003-07-02
ES2202039T3 (es) 2004-04-01
EP1143994A2 (en) 2001-10-17
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01
DE60003632T2 (de) 2004-04-15
IL144228A (en) 2009-06-15
NO20013397D0 (no) 2001-07-09
CA2359392A1 (en) 2000-07-20
US20050271624A1 (en) 2005-12-08
DK1143994T3 (da) 2003-10-20
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL145470A0 (en) Compositions for the treatment of immune diseases
HK1038744A1 (zh) 用於治療炎性疾病的化合物
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
PT1716853E (pt) Utiliza??o de et743 para o tratamento de cancro em seres humanos
AU7528001A (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
PL344451A1 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
GB0001710D0 (en) Therapeutic treatment
EP1079764A4 (en) TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
GB9927757D0 (en) Treatment of autoimmune diseases
HUP0200552A2 (en) Use of apoptosis inducing agents in the treatment of (auto)immune diseases
AU2096002A (en) Therapeutic treatment
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
IL143795A0 (en) Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease
GB9911238D0 (en) Therapeutic use
AU2002365654A8 (en) Treatment of diseases via the skin
GB9910197D0 (en) Multivalent agents for use in the treatment of mitochondrial diseases
GB9911178D0 (en) Agents useful in the treatment of reproductive disorders
GB9901505D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees